Led by experts in the fields of neurology, neurosurgery, drugs and therapeutic devices, Cerebral Therapeutics is pioneering the development of long-term implanted drug-device combination therapies that deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain.

By bypassing the blood-brain barrier, Cerebral Therapeutics’ novel therapies are designed to maximize efficacy while greatly reducing systemic drug exposure and enhancing drug regimen compliance. This unique approach may provide a new solution for patients suffering from chronic neurological diseases, particularly those for whom oral and I.V. infused medicines are not effective and/or are limited by side effects.

The Company is focused initially on addressing the unmet need in treatment-refractory epilepsy, meaning patients who continue to have seizures despite taking conventional orally administered medications.